Multiple system atrophy (MSA) refers to a group of progressive neurodegenerative disorders that affects the basal ganglia and the motor system (parkinsonism), autonomic nervous system (dysautonomia ...

A new study by the University of Turku and Turku University Hospital, Finland, found that a significant proportion of ...

ATH434 is a Disease Modifying Drug Candidate Targeting Parkinsonian Disorders –– Topline Data Expected Mid-Year 2025 –MELBOURNE, Australia and ...

Yoda Therapeutics Inc. (YODA), an AI-driven company that focuses on Central Nervous System (CNS) drugs, today announced the dosing of the first patient in the Phase 2 trial of YA-101 for Multiple ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

Opens in a new tab or window A machine learning model differentiated Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. AUROCs and predictive values for ...

Analyses from Randomized Controlled Trials Further Support the Target Engagement and Safety Profile of Ampreloxetine in Neurodegenerative Disease< ...

A team of researchers from the University of Florida has developed a powerful new tool that uses artificial intelligence (AI) ...

The ATH434-202 is an open label study designed to evaluate the safety, efficacy and target engagement of ATH434 in participants with advanced multiple system atrophy (MSA). “Following the ...